IMUX Q4 2025 Earnings — Immunic, Inc. Revenue & Financial Results | Market Cap Arena

IMUXImmunic, Inc.

$135M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$42,000

Operating Income

-$23M

Net Income

-$19M

EPS (Diluted)

$-0.04

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$24M

Total Liabilities

$31M

Stockholders' Equity

-$7M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$42,000	-$35,000	-20.0%
Operating Income	-$23M	-$26M	+9.0%
Net Income	-$19M	-$25M	+23.3%